Avid Bioservices Inc (CDMO)

[cjgaddy]

Upcoming Sep-Nov: ESMO’14 CRI MSTO SITC ESMO/I-O

UPCOMING EVENTS: http://ir.peregrineinc.com/events.cfm

Sep26-30: “ESMO 2014 (Eur. Society for Medical Oncology)”, Madrid http://www.esmo.org/Conferences/ESMO-2014-Congress (Industry Partner: Peregrine Pharm.)

Oct6: CRI’s 22nd Annual Intl. Cancer Immunotherapy Symposium - "Cancer Immunotherapy: Out of the Gate”, NYC http://tinyurl.com/kvcbggw

Oct16 10:30amPT: Annual Shareholders Meeting (Irvine Marriott) http://ir.peregrineinc.com/events.cfm Proxy 8-28-14 (Def14A): http://tinyurl.com/kvnxgwg

Oct20-23/Avid(booth#1045): BioProcess Intl. (BPI) Conf. & Exhibition, Boston http://convention.bio.org/2014

Oct 30-Nov1: Multidisciplinary Symposium on Thoracic Oncology (MSTO), Chicago http://tinyurl.com/p2l43mt Sponsors: ASTRO, ASCO, IASLC, Univ/Chicago
...Per VP Joe Shan 9-9-14: “Data from the Ph.Ib IST Univ-Pitt. Bavituximab+CP/1stLine/Stage4/NSCLC” (PI=Liza Villaruz, MD)
…Nov1 10-10:30: Speaker Scott J. Antonia (PPHM SAB/KOL/Moffitt), “Immune …Modulation of Lung Cancer”

Nov6-9: SITC 2014 – 29th Annual Meeting, Natl-Harbor MD http://tinyurl.com/l5nkosh (per 9-9-14 C.Call/Jeff Hutchins/J.Shan & Qtly-Fins PR)
...SITC = The Society for Immunotherapy of Cancer http://www.sitcancer.org
...Bavi+Sorafenib/Liver Cancer IST data - "translational data showing immune changes" (5 sites: 3/UTSW, Parkland-Hosp, Dallas/VA, PI: Dr. Adam Yopp)
...Per Jeff Hutchins, 'followup data' from AntiPS+XXX/Melanoma preclin. studies

Nov22: ESMO/I-O: Symposium on Immuno-Oncology 2014, Geneva http://tinyurl.com/ofljfgs
…11:30-11:50am, David Carbone, MD/PhD (Ohio-ST, PPHM KOL/SRB), session=”Advances in Cancer Immunotherapy; from Vaccines to Antibodies & Cell Therapies”, talk=”Immune Checkpoint Inhibitors in Lung Cancer”

Dec7-11/Avid(booth#319): IBC's Antibody Eng. & Therapeutics, HuntingtonBch http://www.ibclifesciences.com/AntibodyEng/overview.xml
.
.
PIPELINE from 9-9-14 Fact Sheet:



= = = = = = = = = = = = =
H. 1st Investigator-Sponsored (IST) Ph.I/II Trial (Bavi+Sorafenib vs. Liver Cancer/HCC, open-label)
...Note: Sorafenib = Onyx/Bayer's Nexavar - see http://www.nexavar.com
Protocol: http://clinicaltrials.gov/ct2/show/NCT01264705 UTSW: http://tinyurl.com/mwdc2ql (5 sites: 3/UTSW, Parkland-Hosp, Dallas/VA, PI=Dr. Adam Yopp)
...4-4-12 AACR'12: Dr. Adam Yopp, "promising safety profile to-date" http://tinyurl.com/7yrwqm7 (see #5591)
...Feb'12-Seo’14 10+ times: CEO Steve King hints of future ex-US partner-driven Bavi+Sorafenib/LIVER trial in Asia: http://tinyurl.com/nkaxtcc
......Articles & Data describe Liver Cancer challenges in Asian populations: http://tinyurl.com/7z7o8j9 & http://tinyurl.com/7z99cy4
...12-1-10: PPHM's 1st IST (Liver Cancer) initiated at UTSW, ~56 patients - http://tinyurl.com/3xd3e6c
…Per S.King, 5-18-10/R&R, "We've had a lot of interest in running clinical trials with the compound from investigators who have either had prior experience with the drug or would like to study the drug in various settings. Potential IST indications include all the major solid tumor types. Of particular interest is Liver Cancer, in which we have a natural tie-in with our HCV program, Ovarian Cancer and Pancreatic Cancer, also very nicely supported by the prior data."

K. 3rd IST Trial (Bavi+PemCarbo vs. Frontline NSCLC, open-label Ph.1B)
Protocol: http://clinicaltrials.gov/ct2/show/NCT01323062
...4-2012: Clinicaltrials.gov shows 2nd site added: Univ. of Pittsburg (Pi=Liza Villaruz, MD)
...4-2-12 AACR'12: "5pts. to-date, 3 have PR's" http://tinyurl.com/7yrwqm7 (see #1744)
...3-8-11: IST (NSCLC) initiated at UNC (PI= J.Grilley-Olson), ~25 patients - http://tinyurl.com/6b926ku